Recently added

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers

Delgado Serrano, Javier; Ferra Coll, Christelle; García-Calderón, Clara Beatriz; Orti Pascual, Guillem; Caballero-Velazquez, Teresa; Lopez Corral, Lucia; VALCARCEL, DAVID (Elsevier, 2025-11-11)

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial

Elez, Elena; Neumann, Ulf; Lang, Sven Arke; Trampe, A. K.; Kasper, Stefan; Salvà, Francesc (Elsevier, 2025-09)

Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review

Zamanillo, Irene; Kuang, Yuting; Uyei, Jennifer; Abrisqueta, Pau; Jimenez-Ubieto, Ana; Serna, Angel (Springer, 2025-09)

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Moore, Kathleen; FABBRO, MICHEL; OMalley, David; Grisham, Rachel; Monk, Bradley; Van Nieuwenhuysen, Els (Elsevier, 2025-11)

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study

MARTELLI, VALENTINO; vidal barrull, joana; Gibert Fernandez, Joan; Fernandez-Rodriguez, Concepción; Linares, Jenniffer; Elez, Elena; García-Alfonso, Pilar; Toledo, Rodrigo; Tabernero, Josep (Elsevier, 2025-09)

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial

Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers ﻿

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial ﻿

Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review ﻿

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer ﻿

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study ﻿

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial

Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study